Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.
CONCLUSION: The beneficial effect of treatment with all active systemic agents on survival (simultaneously or sequentially prescribed) should be taken into account when considering systemic therapy in patients with mCRC. In light of our results, future studies are warranted to clarify the role of potential targeted therapy in elderly mCRC patients, who are often not candidates for combination chemotherapy and treatment with all active cytotoxic agents.
PMID: 27585122 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Razenberg LG, Creemers GJ, Beerepoot LV, Vos AH, van de Wouw AJ, Maas HA, Lemmens VE Tags: Acta Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Palliative | Palliative Care | Study